Literature DB >> 637191

Pulmonary resection for metastatic neoplasms in the lung. Experience at the Massachusetts General Hospital.

E W Wilkins, J M Head, J F Burke.   

Abstract

Cumulative survival in a series of 142 patients undergoing 163 pulmonary resections for metastatic malignant disease is 30% at five years, a statistic that is slightly higher than survival for 820 cases of resection for primary lung carcinoma at the same institution (26%). Removal of pulmonary metastases continues to be a relatively safe approach with hospital mortality of 1.2% and low operative morbidity. Unfavorable predictors, if primary disease is under control, are limited. The primary ones include extent of disease requiring pneumonectomy, melanomatous disease, and appearance of the metastasis antedating knowledge of the primary. An aggressive approach to removal of pulmonary metastases merits continued consideration.

Entities:  

Mesh:

Year:  1978        PMID: 637191     DOI: 10.1016/0002-9610(78)90023-5

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

Review 1.  Review of general surgery 1978.

Authors:  H Ellis
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

2.  Major hepatic resection for metachronous metastases from colon cancer.

Authors:  B Cady; W V McDermott
Journal:  Ann Surg       Date:  1985-02       Impact factor: 12.969

3.  Value of outpatient follow-up after curative surgery for carcinoma of the large bowel.

Authors:  J P Cochrane; J T Williams; R G Faber; W W Slack
Journal:  Br Med J       Date:  1980-03-01

4.  The clinical correlation of an autopsy study of recurrent colorectal cancer.

Authors:  J P Welch; G A Donaldson
Journal:  Ann Surg       Date:  1979-04       Impact factor: 12.969

5.  How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years.

Authors:  Ker Kan Tan; Gilberto de Lima Lopes; Richard Sim
Journal:  J Gastrointest Surg       Date:  2008-12-11       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.